Affiliation:
1. Belgorod State University
2. National Scientific Center «M.D. Strazhesko Institute of Cardiology» of NAMSU
Abstract
A number of studies have now been conducted confirming the relationship between arterial hypertension (AH) and nonalcoholic fatty liver disease (NAFLD). It has been proved that the presence of AH increases or provokes the development of NAFLD. A study of telmisartan effectiveness in combination with atorvastatin and ursodeoxycholic acid (UDCA) in patients with AH and NAFLD was carried out in this article. Material and methods. The study included 39 patients diagnosed with arterial hypertension in combination with NAFLD, who were treated with a combination of drugs: Telmisartan, Atorvastatin and UDCA for 12 weeks. The comparison group consisted of 33 patients with NAFLD who received basic NAFLD therapy without telmisartan and atorvastatin. The study analyzed the efficacy of the prescription of this combination on the clinical condition of patients with AH combined with NAFLD, their hemodynamic parameters, the levels of blood lipid spectrum, IL-6, leptin, adiponectin, and the dynamics of echocardiographic and ultrasonographic parameters. Results and discussion. It has been revealed, that application of telmisartan, atorvastatin and UZHK combination for 12 weeks significantly reduced BP levels to the target values, improved hemodynamic indexes, led to reduction of atherogenic components of blood lipid spectrum. And also prescription of this combination decreased IL-6 and leptin levels, increased adiponectin content, which contributed to improvement of the general state of patients, decrease in the severity of clinical and functional manifestations of NAFLD.
Publisher
Institute of Cytology and Genetics, SB RAS
Reference29 articles.
1. Qian L.-Y., Tu J.-F., Ding Y.-H., Pang J., Che X.-D., Zou H., Huang D.-S. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population. Normal is not the new normal. Medicine (Baltimore). 2016; 95 (29): e4293. doi: 10.1097/MD.0000000000004293
2. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84. doi: 10.1002/hep.28431
3. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15 (1): 11–20. doi: 10.1038/nrgastro.2017.109
4. Federico A., Dallio M., Masarone M., Persico M., Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction. Eur. Rev. Med. Pharmacol. Sci. 2016; 20 (22): 4731–4741.
5. Shishova I.A., Abdulgani Sh., Efremova О.A., Bolkhovitin A.A., Kamyshnikova L.A., Chernobai P.E. Genetic factors of nonalcoholic fatty liver disease against metabolic syndrome. University science: a look into the future: proc. conf., Kursk, 07.02.2020. Kursk: KGMU, 2020. 393–395. [In Russian].